Recently, neoadjuvant systemic therapy (NST) is adopted more and more in the setting of locally advanced breast cancer and early stage breast cancer with special subtypes like human epidermal growth factor receptor 2 positive (HER2+) and triple negative (TN) [2]. This evidence concerns the gene ERBB2 and breast cancer.